Real-world evaluation of teclistamab for the treatment of relapsed/refractory multiple myeloma (RRMM): an International Myeloma Working Group Study.

Blood Cancer J · 2025 · PMC11965530 · PMID 40175336

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

Patients with HRCAs had a lower ORR compared to standard-risk and unknown cytogenetic risk patients (60.8 vs 72.1% vs 70.7%; P = 0.30), but the differences did not reach statistical significance.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.